Prosecution Insights
Prosecution Insights
7 pending office actions • 7 clients • 7 examiners • 7 art units • 0 of 7 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (14%) |
| §103 only | 3 (43%) |
| §102 only | 1 (14%) |
| §112 only | 1 (14%) |
| No statute on record | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.6% | +38.0% |
| PERSONS, JENNA L | 1 | 52.8% | +65.0% |
| BAEK, JONGHWAN NMN | 1 | 66.7% | +0.0% |
| HAM, JIEUN | 1 | 50.0% | +0.0% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.4% | +41.3% |
| HORTH, LISA ANNE | 1 | 61.8% | +44.1% |
| COUNTS, GARY W | 1 | 58.9% | +29.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17806932 | METHOD AND BIOMARKER FOR DETECTION OR DIAGNOSIS OF MYOCARDIAL INFARCTION | HORTH, LISA ANNE | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18747694 | CELLS FOR GLYCOENGINEERING AND METHODS OF USE | PERSONS, JENNA L | 85d overdue |
| 17808476 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | ABDALHAMEED, MANAHIL MIRGHANI ALI | 25d overdue |
| 17595830 | COMPANION DIAGNOSTIC ASSAY FOR GLOBO-H RELATED CANCER THERAPY | COUNTS, GARY W | 11d overdue |
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | SALMON, KATHERINE D | 9d |
| 17806932 | METHOD AND BIOMARKER FOR DETECTION OR DIAGNOSIS OF MYOCARDIAL INFARCTION | HORTH, LISA ANNE | 13d |
| Client (Assignee) | Pending OAs |
|---|---|
| EG BIOMED CO., LTD. | 1 |
| Rock BioMedical Inc. | 1 |
| China Medical University | 1 |
| OBI Pharma, Inc. | 1 |
| Yoda Therapeutics | 1 |
| Academia Sinica | 1 |
| Ming-Tain Lai | 1 |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1637 | 1 |
| 1618 | 1 |
| 1643 | 1 |
| 1622 | 1 |
| 1681 | 1 |
| 1678 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | Eg Biomed Co., Ltd. | SALMON, KATHERINE D | 1682 | §103 | Non-Final OA | 9d | Pending | Dec 11, 2024 |
| 18747694 | CELLS FOR GLYCOENGINEERING AND METHODS OF USE | Rock Biomedical Inc. | PERSONS, JENNA L | 1637 | §112 | Non-Final OA | 85d overdue | Pending | Jun 19, 2024 |
| 18335897 | NANOCAPSULE AND USES THEREOF | China Medical University | BAEK, JONGHWAN NMN | 1618 | Other | Non-Final OA | 22d overdue | Pending | Jun 15, 2023 |
| 18253576 | ACTIVE CANCER IMMUNOTHERAPY BY IMMUNE MODULATION VIA GLOBO SERIES ANTIGENS | Obi Pharma, Inc. | HAM, JIEUN | 1643 | §103 | Non-Final OA | 28d overdue | Pending | May 18, 2023 |
| 17808476 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | Yoda Therapeutics Inc. | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §102 | Final Rejection | 25d overdue | Pending | Jun 23, 2022 |
| 17806932 | METHOD AND BIOMARKER FOR DETECTION OR DIAGNOSIS OF MYOCARDIAL INFARCTION | Academia Sinica | HORTH, LISA ANNE | 1681 | §101 | Final Rejection | 13d | Pending | Jun 14, 2022 |
| 17595830 | COMPANION DIAGNOSTIC ASSAY FOR GLOBO-H RELATED CANCER THERAPY | Ming-Tain Lai | COUNTS, GARY W | 1678 | §103 | Non-Final OA | 11d overdue | Pending | Nov 24, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial